Nektar Therapeutics (NKTR)

$17.18 0.00 (0.00%)

16:10 EDT NKTR Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 2.94B

PE Ratio -21.48

EPS -0.8

Volume (Avg. Vol.)

Day's Range 17.18 - 17.18

52-Week Range 13.63 - 28.60

Dividend & Yield N/A (N/A)

NKTR Stock Predictions, Articles, and Nektar Therapeutics News

From InvestorPlace
From the Web

7 Big Biotech Stocks to Avoid

By Louis Navellier, Editor, Growth Investor Jan 28, 2020

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list. Here's why.

7 Worst Stocks in the S&P 500 in 2019

By Luke Lango, InvestorPlace Markets Analyst Sep 20, 2019

While the markets have roared higher in 2019, these stocks have been crashing. But some of them could rebound soon.

8 Biotech Stocks to Watch After the Q2 Earnings Season

By Chris Lau, InvestorPlace Contributor Aug 20, 2019

Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.

3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics

By James Brumley, InvestorPlace Feature Writer Jun 14, 2019

Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.

10 Oversold Stocks to Run From

By James Brumley, InvestorPlace Feature Writer Apr 23, 2019

Wells Fargo, HP and Gilead Sciences are just three oversold stocks to sell before they lose any more ground.

9 U.S. Stocks That Are Coming to Life Again

By James Brumley, InvestorPlace Feature Writer Feb 12, 2019

All-American U.S. stocks like Foot Locker, Copart and Snapchat are on the mend for all the right reasons. here are the charts to watch.

7 Biotech Stocks to Buy Now

By Chris Lau, InvestorPlace Contributor Sep 19, 2018

Biotech companies are recovering nicely this year. With a quarter left to go, the upside potential is high for those biotech stocks that dipped recently.

3 Big Stock Charts for Friday: Nektar Therapeutics, Waters and A.O. Smith

By James Brumley, InvestorPlace Feature Writer Aug 10, 2018

As we move into the weekend, the stock charts of AOS, NKTR and WAT should be on your radar.

5 Big Pharma Stocks Investors Love Right Now

By Chris Lau, InvestorPlace Contributor Jul 13, 2018

The biotechnology and pharmaceutical sectors continue to offer great value for investors, and these five Big Pharma stocks stand out from the crowd.

Nektar Therapeutics Stock Is a Buy After a Major Market Misread

By Chris Lau, InvestorPlace Contributor Jun 5, 2018

Sellers dominated the trading action on Nektar stock after its preliminary clinical results. Over-reaction or justified selling? The market simply did not understand the results, hurting the NKTR stock price.

Why Bristol-Myers Squibb Company Shares Are Down Today

By Karl Utermohlen, InvestorPlace Writer Jun 4, 2018

Bristol-Myers Squibb Company (BMY) shares were sliding as the company's collaboration cancer drug with Nektar Therapeutics (NKTR) did not impress investors.

Why Nektar Therapeutics Shares Are Plunging Today

By William White, InvestorPlace Writer Jun 4, 2018

Nektar Therapeutics (NKTR) took a heavy hit on Monday following the release of preliminary results from a recent clinical trial.

Nektar Therapeutics Stock Is Risky But Offers Big Reward

By Chris Lau, InvestorPlace Contributor May 15, 2018

Nektar Therapeutics pulled back in recent weeks, and that is a good thing. Valuations are stretched, but the upside in NKTR stock is high if management delivers.

3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG)

By Karl Utermohlen, InvestorPlace Writer May 11, 2018

Alphabet Inc (GOOG,GOOGL) is fixing latency issues with Google Home Max, while Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG) reported earnings.